Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
about
Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaAGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AMLIdelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cellsSynthesis, characterization and apoptotic activity of quinazolinone Schiff base derivatives toward MCF-7 cells via intrinsic and extrinsic apoptosis pathways.Ligand-Guided Selection of Target-Specific Aptamers: A Screening Technology for Identifying Specific Aptamers Against Cell-Surface Proteins.Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.Ibrutinib: first global approval.Tumor suppressors in follicular lymphoma.Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Ibrutinib: from bench side to clinical implications.Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells.Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.
P2860
Q28087378-1DAD1AC4-DEB6-4C94-BDC7-4695C28FBB7EQ30403563-4B301F5B-93AB-44FE-BF9A-0EDB0E812CECQ33424543-1AF7F7ED-6171-4CEF-9CD5-F26D63A4F13FQ34747359-A7AC9584-7BC7-4B0A-9FF3-FAC79A3E718CQ34855819-0DDAF2E3-49E0-4572-BC82-B416E531216BQ35778773-B193BA72-D74A-4424-9FDA-8F2DF43F8DDCQ36009344-5FD961F1-4B8A-4A3A-8B2B-9B405E112169Q36213629-4065291E-C144-430C-949C-1F12420C80D5Q38181979-0D69557E-A5EA-4BE6-A217-275F192C0FD2Q38266066-AE22CF9F-7CF1-4346-AB9B-F332E87FE1EDQ38375141-7DE7EA20-8186-4112-B517-0BA45836274CQ38544216-B017DD50-5988-40E3-B5AC-67F880379879Q38557067-729DDDD3-F0F8-422F-8A99-8342EFF7BFA2Q38755091-7E99D569-5A9B-4BBD-B065-6D8475B66CBEQ38862584-E982A482-D018-4C85-9339-95F672D4FBB1Q38972048-38CFF70B-BDC2-414C-98BB-7186C9144BEBQ47163960-292AFE4E-0DD1-4C5B-9E37-70B7EC6B8DA0Q52431673-09241FD2-0C9E-4D4E-9272-C8A1D770530E
P2860
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
@en
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
@nl
type
label
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
@en
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
@nl
prefLabel
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
@en
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
@nl
P2860
P1476
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
@en
P2093
Alexey V Danilov
P2860
P304
P356
10.1016/J.CLINTHERA.2013.08.004
P577
2013-09-01T00:00:00Z